WO1995011682A3 - Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents - Google Patents

Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents Download PDF

Info

Publication number
WO1995011682A3
WO1995011682A3 PCT/US1994/012017 US9412017W WO9511682A3 WO 1995011682 A3 WO1995011682 A3 WO 1995011682A3 US 9412017 W US9412017 W US 9412017W WO 9511682 A3 WO9511682 A3 WO 9511682A3
Authority
WO
WIPO (PCT)
Prior art keywords
therapeutic agents
arylalkenyl
arylalkyl
derivatives
heptenoic acid
Prior art date
Application number
PCT/US1994/012017
Other languages
French (fr)
Other versions
WO1995011682A2 (en
Inventor
Steven W Andrews
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to EP94931938A priority Critical patent/EP0725643B1/en
Priority to AT94931938T priority patent/ATE216890T1/en
Priority to JP7512713A priority patent/JPH09506081A/en
Priority to AU80844/94A priority patent/AU8084494A/en
Priority to DE69430538T priority patent/DE69430538T2/en
Publication of WO1995011682A2 publication Critical patent/WO1995011682A2/en
Publication of WO1995011682A3 publication Critical patent/WO1995011682A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Abstract

The present invention provides therapeutic agents comprising cyclopentane heptane or heptenoic acid, 2 arylalkyl or arylalkenyl and derivatives thereof, wherein the carboxylic acid of the parent compound is converted to a hydroxyl or ester group. These therapeutic agents are potent ocular hypotensives as well as having other therapeutic uses.
PCT/US1994/012017 1993-10-28 1994-10-20 Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents WO1995011682A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP94931938A EP0725643B1 (en) 1993-10-28 1994-10-20 Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
AT94931938T ATE216890T1 (en) 1993-10-28 1994-10-20 2-AZYLALKYL OR ARYLALENYL CYCLOPENTANHEPTANE AND HEPTENE ACIDS, DERIVATIVES AND THERAPEUTIC USE
JP7512713A JPH09506081A (en) 1993-10-28 1994-10-20 Cyclopentane heptane or heptenoic acid, 2-arylalkyl or arylalkenyls and derivatives as pharmaceuticals
AU80844/94A AU8084494A (en) 1993-10-28 1994-10-20 Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
DE69430538T DE69430538T2 (en) 1993-10-28 1994-10-20 2-AZYLALKYL OR ARYLALENYL CYCLOPENTANEHEPTANIC AND HEPTENIC ACIDS, DERIVATIVES AND THERAPEUTIC APPLICATION

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/144,968 US5486540A (en) 1993-10-28 1993-10-28 Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
US08/144,968 1993-10-28

Publications (2)

Publication Number Publication Date
WO1995011682A2 WO1995011682A2 (en) 1995-05-04
WO1995011682A3 true WO1995011682A3 (en) 1995-05-18

Family

ID=22510998

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/012017 WO1995011682A2 (en) 1993-10-28 1994-10-20 Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents

Country Status (9)

Country Link
US (1) US5486540A (en)
EP (1) EP0725643B1 (en)
JP (1) JPH09506081A (en)
AT (1) ATE216890T1 (en)
AU (1) AU8084494A (en)
CA (1) CA2175076A1 (en)
DE (1) DE69430538T2 (en)
ES (1) ES2176262T3 (en)
WO (1) WO1995011682A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5258698A (en) 1996-11-12 1998-06-03 Alcon Laboratories, Inc. 15-ketal prostaglandins for the treatment of glaucoma or ocular hypertension
CN1243548C (en) * 2000-09-13 2006-03-01 参天制药株式会社 Eye drops
US7842727B2 (en) * 2001-03-27 2010-11-30 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US6495719B2 (en) * 2001-03-27 2002-12-17 Circagen Pharmaceutical Histone deacetylase inhibitors
US7312247B2 (en) * 2001-03-27 2007-12-25 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
US8026280B2 (en) 2001-03-27 2011-09-27 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
EP1511477A4 (en) * 2002-05-22 2008-04-09 Errant Gene Therapeutics Llc Histone deacetylase inhibitors based on alpha-ketoepoxide compounds
CA2506504A1 (en) * 2002-11-20 2004-06-03 Errant Gene Therapeutics, Llc Treatment of lung cells with histone deacetylase inhibitors
EP1666043B1 (en) * 2003-07-31 2009-12-02 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
US7183310B2 (en) * 2004-08-10 2007-02-27 Allergan, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
CA2587013A1 (en) * 2004-11-08 2006-05-18 Errant Gene Therapeutics, Llc Histone deacetylase inhibitors
CN102526064A (en) * 2004-12-09 2012-07-04 参天制药株式会社 Product containing prostaglandin having fluorine atom in its molecule
PL1829545T3 (en) * 2004-12-24 2012-09-28 Santen Pharmaceutical Co Ltd Prostaglandin f2 alpha derivative containing products
US7618500B2 (en) * 2005-11-14 2009-11-17 Lawrence Livermore National Security, Llc Corrosion resistant amorphous metals and methods of forming corrosion resistant amorphous metals
JPWO2007097205A1 (en) * 2006-02-02 2009-07-09 憲次 吉田 Eye drops

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2289170A1 (en) * 1974-11-01 1976-05-28 May & Baker Ltd CYCLOPENTANE DERIVATIVES
FR2293923A1 (en) * 1974-12-11 1976-07-09 Pfizer 11-DESOXY-O-PENTANORPROSTAGLANDINS SUBSTITUTED IN POSITION 15
JPS53135956A (en) * 1978-02-04 1978-11-28 Pfizer 111deoxyyomegaapentanol prostaglandin
WO1990002553A1 (en) * 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
WO1994006433A1 (en) * 1992-09-21 1994-03-31 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
WO1994006432A1 (en) * 1992-09-24 1994-03-31 Allergan, Inc. Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl)-5-heptenoic acids and derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
DE3220156C2 (en) * 1982-05-28 1990-01-25 Heida Houston Tex. Thurlow Cooking and roasting utensils with lids provided with metal handles, in particular stainless steel handles
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2289170A1 (en) * 1974-11-01 1976-05-28 May & Baker Ltd CYCLOPENTANE DERIVATIVES
FR2293923A1 (en) * 1974-12-11 1976-07-09 Pfizer 11-DESOXY-O-PENTANORPROSTAGLANDINS SUBSTITUTED IN POSITION 15
JPS53135956A (en) * 1978-02-04 1978-11-28 Pfizer 111deoxyyomegaapentanol prostaglandin
WO1990002553A1 (en) * 1988-09-06 1990-03-22 Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
WO1994006433A1 (en) * 1992-09-21 1994-03-31 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
WO1994006432A1 (en) * 1992-09-24 1994-03-31 Allergan, Inc. Method of lowering intraocular pressure by administering a pharmaceutical composition containing 7-(5-substituted cyclopentyl) and 7-(5-substituted-cyclopentenyl)-5-heptenoic acids and derivatives

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, vol. 90, Columbus, Ohio, US; abstract no. 103508J *
M.P.L. CATON ET AL.: "SYNTHESIS OF SOME NOVEL 11--DEOXYPROSTAGLANDINS, pages 27-38, *
S.M. ROBERTS AND F. SCHEINMANN "CHEMISTRY, BIOCHEMISTRY AND PHARMACOLOGICAL ACTIVITY OF PROSTANOIDS", PERGAMON *

Also Published As

Publication number Publication date
JPH09506081A (en) 1997-06-17
ATE216890T1 (en) 2002-05-15
EP0725643B1 (en) 2002-05-02
CA2175076A1 (en) 1995-05-04
US5486540A (en) 1996-01-23
WO1995011682A2 (en) 1995-05-04
AU8084494A (en) 1995-05-22
EP0725643A1 (en) 1996-08-14
ES2176262T3 (en) 2002-12-01
DE69430538T2 (en) 2003-01-09
DE69430538D1 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
WO1995011682A3 (en) Cyclopentane heptanoic or heptenoic acid, 2-arylalkyl or arylalkenyl and derivatives as therapeutic agents
AU5779400A (en) Process for the preparation of 3,3-dimethylbutanal
AU5485698A (en) Oxyiminopregnancarbolactone
CA2135751A1 (en) 4-Mercaptoacetylamino-[2] Benzazepinone(3) Derivatives, and Use as Enkephalinase Inhibitors
HK1027748A1 (en) Use of 3-benzoyl-phenylacetic acids, esters, or amides for treatment of glcia glaucoma
MY118354A (en) 1,3-propane diol derivatives as bioactive compounds
AU5246596A (en) Compounds as intermediates
EP1348437A3 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2183315A1 (en) Novel Mercaptoacetylamido 1,3,4,5-Tetrahydro-Benzo[c]azepin-3-One Disulfide Derivatives Useful as Inhibitors of Enkephalinase and Ace
AU3126600A (en) N-ureidoalkyl-piperidines as modulators of chemokine receptor activity
AU674378B2 (en) Use of 2-amino-6-A-propylamino-4,5,6, 7-tetrahydrobenzothiazole (pramipexol) as an anti-depressantdrug
EP0824910A3 (en) Use of a Krill Enzyme for the Treatment of Dental Plaque
CA2194885A1 (en) Substituted benzamidines, their preparation and their use as pharmaceutical compounds
CA2127878A1 (en) FO-1289 Substance and Its Production
AU8974298A (en) 1,4,7,10-tetraazabicyclo{8.2.2}tetradecan-2-one, a process for the preparation thereof and the use thereof for the preparation of tetraazamacrocycles
AU5835190A (en) Antitumor substance be-13793c
AU1306795A (en) Anticonvulsant pseudofructopyranose sulfamates
CA2251132A1 (en) Use of phosphinyloxyalkyl and phosphonamidoalkyl derivatives of cyclopentane(ene) as therapeutic agents
EP0719541A4 (en) Skin activator having glycosaminoglycan production accelerator activity
CA2114830A1 (en) Lactone Compound and Process of Production Thereof
EP1016408A4 (en) C-c chemokine production inhibitor
AU6203396A (en) Activated immunoglobulin
CA2123083A1 (en) Uses of 1,1,1,3,3,3-hexafluoropropane
EP0414903A4 (en) New thioproline derivative
WO1996021670A3 (en) Antifungal fusacandins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SK UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 1994931938

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2175076

Country of ref document: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1994931938

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1994931938

Country of ref document: EP